Effect of long-term therapy with AT1angiotensin II receptor blockers in combination with aldosterone receptor inhibitor on ischemic myocardial remodelling and chronic heart failure
https://doi.org/10.21518/2079-701X-2014-12-81-85
Abstract
The article presents the results of a 6-month long-term therapy with angiotensin II receptor blocker Valsacor and aldosterone receptor blocker Spironolactone in patients with chronic heart failure (CHF) against a background of ischemic and/or post-infarction left ventricular remodelling. The results show that the renin-angiotensin-aldosterone system (RAAS) blockade in the combination therapy slows down the pathological remodelling of the left ventricle (LV) and thus prevents progression of CHF in a majority of patients with myocardial infarction (MI).
About the Authors
AT Teplyakov
Tomsk Research Institute of Cardiology
Russian Federation
Russian Federation
EV Grakova
Tomsk Research Institute of Cardiology
Russian Federation
Russian Federation
AV Andrianova
Tomsk Research Institute of Cardiology
Russian Federation
Russian Federation
Е. EY Pushnikova
Tomsk Research Institute of Cardiology
Russian Federation
Russian Federation
Н. NV Protopopova
Tomsk Research Institute of Cardiology
Russian Federation
Russian Federation
Р. RS Karpov
Tomsk Research Institute of Cardiology
Russian Federation
Russian Federation
References
1. Беленков Ю.Н. и др. Хроническая сердечная недостаточность. Избранные лекции по кардиологии. М.: ГЭОТАР-Медиа, 2006: 432.
2. Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan in Acute Myocardial Infarction Trial Investigators.Valsartan, capto-pril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med, 2003, 349(20): 1893-1906. '
3. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA. CHARM Investigators and CommitteesEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet, 2003, 362(9386): 767-771.
4. Yusuf S, Pfeffer MA, Swedberg K et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet, 2003, 362(9386): 777-781.
5. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet, 2000, 355(9215): 1582-1587.
6. Konstam MA, Neaton JD, Dickstein K et al. for the HEAAL Investigators. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet, 2009, 374(9704): 1840-1848.
7. The ONTARGET Investigators. Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. Engl J Med, 2008,358: 1547-1559.
8. Mancia G, Fagard R et al. Guidelines for the management of arterial hypertension. TheTask Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Hypertension, 2007, 25 (6): 1105-1187.
9. Максимов М.Л., Дербенцева Е.А., Дралова О.В. и др. Применение блокатора АТ1-рецепторов ангиотензина II валсартана у пациентов с ХСН. Сердечная недостаточность, 2010, 5(61): 301-305.
10. Montezano AC, Callera GE, Yogi A et al. Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways. Arterioscler. Thromb. Vasc. Biol, 2008, 28 (8): 1511-1518.
Review
For citations:
Teplyakov A, Grakova E, Andrianova A, Pushnikova E, Protopopova N, Karpov R. Effect of long-term therapy with AT1angiotensin II receptor blockers in combination with aldosterone receptor inhibitor on ischemic myocardial remodelling and chronic heart failure. Meditsinskiy sovet = Medical Council. 2014;(12):81-85. (In Russ.) https://doi.org/10.21518/2079-701X-2014-12-81-85
Views:
384
Email this article 